Important Information for ModivCare Securities Purchasers: Rosen Law Firm Reminds Investors of Upcoming Deadline
New York, NY – Rosen Law Firm, a global investor rights law firm, reminds purchasers of ModivCare Inc. (MODV) securities between November 3, 2022, and September 15, 2024 (the “Class Period”), of the significant March 31, 2025 lead plaintiff deadline. This deadline pertains to a securities class action lawsuit filed against ModivCare in the United States District Court for the Southern District of New York.
Background
ModivCare is a healthcare services company that provides a range of services, including home health, hospice, and personal care. The company went public through a merger with InnovAge Holding Corp. in November 2022. The securities class action lawsuit alleges that ModivCare and certain of its executives made false and misleading statements regarding the company’s business, operations, and financial condition.
Impact on Investors
If you purchased ModivCare securities during the Class Period, you may be eligible to participate in the securities class action lawsuit. The lead plaintiff deadline, which is rapidly approaching, is March 31, 2025. If you wish to act as a lead plaintiff, you must file a motion with the Court no later than this date. The lead plaintiff is a court-appointed representative for absent class members. As a lead plaintiff, you may have the opportunity to help direct the litigation and make important decisions, including whether to accept a settlement.
Under the terms of the contingency fee arrangement, you would not be required to pay any out-of-pocket fees or costs. Instead, the law firm would be compensated from any recovery obtained for the class. This means that you would not bear any financial risk.
Impact on the World
The securities class action lawsuit against ModivCare is not only significant for investors but also for the healthcare industry as a whole. The allegations in the lawsuit, if proven true, could have far-reaching consequences. For instance, they could lead to increased scrutiny and regulation of healthcare services companies. Moreover, they could potentially damage the reputation of the entire industry, which could negatively impact investor confidence and, ultimately, the value of healthcare stocks.
Conclusion
If you purchased ModivCare securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs. The lead plaintiff deadline is fast approaching, so it is essential that you act quickly if you wish to participate in the securities class action lawsuit. The contingency fee arrangement means that you would not bear any financial risk. Furthermore, the outcome of this lawsuit could have significant implications for the healthcare industry as a whole.
- Rosen Law Firm reminds ModivCare securities purchasers of the March 31, 2025, lead plaintiff deadline.
- If you purchased ModivCare securities during the Class Period, you may be eligible to participate in the securities class action lawsuit.
- Under the contingency fee arrangement, you would not be required to pay any out-of-pocket fees or costs.
- The outcome of this lawsuit could have significant implications for the healthcare industry as a whole.
